BiomX (NYSEMKT:PHGE) Trading Down 49.5% – Time to Sell?

BiomX Inc. (NYSEMKT:PHGE) shares traded down 49.5% during mid-day trading on Wednesday . The stock traded as low as $0.7201 and last traded at $0.3730. 53,300 shares traded hands during trading, a decline of 85% from the average session volume of 347,190 shares. The stock had previously closed at $0.7390.

BiomX Stock Performance

The stock’s 50-day moving average is $0.52 and its 200-day moving average is $0.50. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.84 and a quick ratio of 2.84. The stock has a market cap of $9.91 million, a price-to-earnings ratio of -0.50 and a beta of 1.46.

Institutional Trading of BiomX

Several institutional investors have recently made changes to their positions in the stock. AIGH Capital Management LLC grew its stake in BiomX by 81.1% during the first quarter. AIGH Capital Management LLC now owns 1,566,944 shares of the company’s stock worth $871,000 after buying an additional 701,544 shares during the period. Warberg Asset Management LLC bought a new stake in shares of BiomX during the 1st quarter valued at about $55,000. Nantahala Capital Management LLC lifted its holdings in shares of BiomX by 44.1% in the 1st quarter. Nantahala Capital Management LLC now owns 2,493,309 shares of the company’s stock worth $1,386,000 after purchasing an additional 762,709 shares during the last quarter. ADAR1 Capital Management LLC bought a new position in shares of BiomX during the first quarter worth about $166,000. Finally, Alyeska Investment Group L.P. increased its stake in shares of BiomX by 83.8% in the first quarter. Alyeska Investment Group L.P. now owns 1,590,738 shares of the company’s stock valued at $884,000 after purchasing an additional 725,338 shares during the period. 40.57% of the stock is owned by hedge funds and other institutional investors.

BiomX Company Profile

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.